Evista
(Raloxifene)ApprovedSmall molecule
Eli LillyRaloxifene is used to prevent and treat osteoporosis in postmenopausal women, and it also reduces the risk of breast cancer in women at high risk for the disease.[2] Evista is currently approved and in use across 10 indications[4].[1]
Evista is one of 272 small molecule programs targeting Postmenopausal Osteoporosis. It is currently in Approved.
10
Indications
52
Total Trials
3
Active Trials
271
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
174 competitors in Schizophrenia
#DrugCompanyPhaseTrials
1Evista
Eli LillyApproved
Ozempic
Novo NordiskPreclinical
Resotran
TakedaPreclinical
Inapsine
Jazz PharmaceuticalsPreclinical
Depakote
AbbViePreclinical
Ibrance
PfizerPreclinical
Lunesta
Akero TherapeuticsPreclinical
Luvox
SSolvay Pharmaceuticals
Preclinical
Catapres
Boehringer IngelheimPreclinical
Rapamune
PPrism Pharmaceuticals
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Osteoporosis7 trials
Breast Cancer5 trials
Schizophrenia4 trials
Alzheimer's Disease2 trials
29 more indications
Postmenopausal Osteoporosis2 trials
Polycystic Ovarian Syndrome2 trials
Prostate Cancer1 trial
Fracture1 trial
Replication of the HORIZON Pivotal Fracture Trial in Healthcare Claims Data
Completed·—··NCT04736693·18,028 enrolled
COVID-191 trial
Postmenopausal Women1 trial
Low Bone Mineral Density1 trial
Prevention1 trial
Benign Prostatic Hyperplasia1 trial
New Treatment Strategies and Epigenetic Biomarker for Management of Benign Prostatic Hyperplasia
Recruiting·—·Phase 2·NCT06944145·242 enrolled
Randomized1 trial
Hot flashes1 trial
Radiation Therapy1 trial
Memantine +/- Raloxifene for Cognitive Preservation After Radiation Therapy to the Brain
Not yet recruiting·TThe University of Texas Health Science Center at San Antonio·Phase 2·NCT07470606·108 enrolled
Esophageal Cancer1 trial
Endometriosis1 trial
Hormone Replacement Therapy1 trial
Observational Study1 trial
Endometrial Cancer1 trial
Schizoaffective Disorder1 trial
Regulatory
FDA Approval Timeline[5]
Dec 9, 1997
EVISTA
NDA NDA020815
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Evista drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Raloxifene. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]